skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8799

Amino acid management of Parkinson’s disease: a case study

Case report

(11210) Views  (1697) Full article downloads

Authors: Marty Hinz, Alvin Stein, Thomas Uncini

Published Date February 2011 Volume 2011:4 Pages 165 - 174
DOI: http://dx.doi.org/10.2147/IJGM.S16621

Marty Hinz1, Alvin Stein2, Thomas Uncini3
1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3DBS Labs, Duluth, MN, USA

Abstract: An extensive list of side effects and problems are associated with the administration of L-dopa (L-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These problems can preclude achieving an optimal response with L-dopa treatment.
Purpose: To present a case study outlining a novel approach for the treatment of Parkinson’s disease that allows for management of problems associated with L-dopa administration and discusses the scientific basis for this treatment.
Patients and methods: The case study was selected from a database containing 254 Parkinson’s patients treated in developing and refining this novel approach to its current state. The spectrum of patients comprising this database range from newly diagnosed, with no previous treatment, to those who were diagnosed more than 20 years before and had virtually exhausted all medical treatment options. Parkinson’s disease is associated with depletion of tyrosine hydroxylase, dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that administration of L-dopa may deplete L-tyrosine, L-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, and sulfur amino acids. The properly balanced administration of L-dopa in conjunction with 5-HTP, L-tyrosine, L-cysteine, and cofactors under the guidance of organic cation transporter functional status determination (herein referred to as “OCT assay interpretation”) of urinary serotonin and dopamine, is at the heart of this novel treatment protocol.
Results: When 5-HTP and L-dopa are administered in proper balance along with L-tyrosine, L-cysteine, and cofactors under the guidance of OCT assay interpretation, the long list of problems that can interfere with optimum administration of L-dopa becomes controllable and manageable or does not occur at all. Patient treatment then becomes more effective by allowing the implementation of the optimal dosing levels of L-dopa needed for the relief of symptoms without the dosing value barriers imposed by side effects and adverse reactions seen in the past.

Keywords: Parkinson’s, Parkinsonism, Parkinson’s disease, L-dopa, 5-HTP




 

Other articles by Dr Marty Hinz

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid-responsive Crohn's disease: a case study
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Monoamine depletion by reuptake inhibitors
Neurotransmitter testing of the urine: a comprehensive analysis
Relative nutritional deficiencies associated with centrally acting monoamines
The discrediting of the monoamine hypothesis
The dual-gate lumen model of renal monoamine transport
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”


Readers of this article also read:
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University